Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP)
- 14 May 2020
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 27 (3) , 410-419
Abstract
Background: Natalizumab is a highly efficacious therapy for relapsing–remitting multiple sclerosis (RRMS). Patients who discontinue natalizumab may experience return of MS disease activity. Objective: The aim of this study was to analyze predictors of post-natalizumab disease activity return. Methods: The Tysabri® Observational Program (TOP) is an ongoing observational study of natalizumab-treated RRMS patients. Patients discontinuing natalizumab are encouraged to remain in TOP. Results: Analyses included 3221 TOP patients. After ⩾2 years on natalizumab, relapse risk was twice as high for patients who switched to an oral therapy ( n = 660, hazard ratio (HR) = 2.18, p < 0.001) and three times as high for patients who switched to an injectable therapy ( n = 95, HR = 3.02, p < 0.001) as for those who stayed on natalizumab ( n = 2466). Relapse rates after switching remained below pre-natalizumab rates. In patients who switched to an oral therapy, higher relapse risk was predicted by longer washout time, more pre-natalizumab relapses, higher Expanded Disability Status Scale score at natalizumab initiation, and shorter natalizumab treatment duration. Conclusion: Patients who stayed on natalizumab had better clinical outcomes than those who switched to an oral or injectable therapy after ⩾2 years on natalizumab. These results highlight modifiable risk factors for disease activity return (e.g. natalizumab treatment duration and washout duration) to consider when making treatment decisions.Keywords
Funding Information
- Biogen (N/A)
This publication has 24 references indexed in Scilit:
- Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathyAnnals of Neurology, 2014
- Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patientsMultiple Sclerosis and Related Disorders, 2014
- MS disease activity in RESTORENeurology, 2014
- Switching From Natalizumab to Fingolimod in Multiple SclerosisJAMA Neurology, 2014
- Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme resultsJournal of Neurology, Neurosurgery & Psychiatry, 2014
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialThe Lancet, 2012
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2012
- Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumabMultiple Sclerosis Journal, 2012
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosisNeurology, 2011
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006